26. August 2019

New automated FXIII activity assay

Zedira kits

Zedira Logo                                                                                                                                                                     Transglutaminase-Newsletter | August 2019

Paving the way to a new automated FXIII activity assay!

Just recently, Technoclone (Vienna, Austria) and Zedira presented a joint poster at the 27th ISTH Congress in Melbourne, Australia. The scientists involved, Martina Leiter, Ralf Pasternack, Christian Büchold, and Nikolaus Binder concluded:
“The fully automated TECHNOFLUOR FXIII Activity assay run on the new Ceveron s100 haemostasis analyzer is an appropriate method for fast and accurate determination of this critical factor in the stabilization of blood clots. With a high degree of linearity over a wide assay range, this new assay shows excellent recovery of EQA samples, demonstrating high agreement with other FXIII activity assays on the market.”

In this context, please find below our reagents targeting FXIII (F13, plasma transglutaminase) flanked by selected coagulation products:

Selection of Factor XIII products


Art. No. Name Unit Price


FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH 10 mg 520 €

FXIII-Assay Kit

1 Kit 575 €


Art. No. Name Unit Price


1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride 10 mg 480 €

Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-Pro-OH 5 mg 480 €

Special product

Art. No. Name Unit Price


Gly-Pro-Arg-Pro-amide 25 mg 370 €


Art. No. Name Unit Price


Human blood coagulation Factor XIII-A, recombinant 200 µg 370 €

Human Factor XIIIa, activated 200 µg 520 €

Human blood coagulation Factor XIII B subunit 200 µg 370 €


Art. No. Name Unit Price

 T222 Human alpha Thrombin, recombinant 100 NIH Units 185 €


Art. No. Name Unit Price


Polyclonal antibody to human blood coagulation factor XIII (A-subunit) 500 µg 365 €

FITC-labeled polyclonal antibody to human factor XIII (A-subunit) 200 µg 395 €

Polyclonal antibody to human blood coagulation factor XIII (B-subunit) 200 µg 365 €

FITC-labeled polyclonal antibody to human factor XIII (B-subunit) 200 µg 395 €

DD-XLink-mab 100 µg 365 €

Drug Discovery at Zedira targeting FXIIIa

Zedira developed direct-acting FXIIIa blockers for safe anticoagulation. This unique and promising approach has the potential of a significant reduction in the life-threatening tendency to bleeding as provoked by current drugs. Zedira scientists used structure-assisted drug design to develop potent and selective compounds while deciphering the structure of active coagulation factor XIII.

FXIII active structure
Structure of Active Coagulation Factor XIII
In the inactive state, recombinant FXIII exists as a dimer. Upon binding of the irreversible acting blocker ZED1301 (A108) and three calcium ions per subunit, FXIII dissociates and the ß-barrel 1 and ß-barrel 2 domains undergo a remarkable shift exposing the active site (upper left). The crystal structure of FXIII in its active conformation provides detailed information on an atomic level regarding the role of calcium in the activation process. Calcium coordination affects the shape of the active site of FXIII and triggers the formation of the catalytic dyad (H342, E401).


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • European Congress on Thrombosis and Haemostasis

    02.10.2019 - 04.10.2019
    Glasgow, United Kingdom

  • World ADC London 2020

    02.03.2020 - 05.03.2020
    London, Great Britain

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA